Opus Genetics Inc (IRD)

Currency in USD
4.040
+0.060(+1.51%)
Closed·
4.100+0.060(+1.49%)
·
Advertisement
IRD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.8854.080
52 wk Range
1.7007.070
Key Statistics
Prev. Close
4.04
Open
3.94
Day's Range
3.885-4.08
52 wk Range
1.7-7.07
Volume
975.3K
Average Volume (3m)
2.54M
1-Year Change
132.1839%
Book Value / Share
0.46
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IRD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.941
Upside
+245.08%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings downwards for the upcoming period

Opus Genetics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

17 Buy
0 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 13.941
(+245.08% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
RBC Capital
Buy11.00+172.28%9.00Maintain11/11/2026
H.C. Wainwright
Buy14.00+246.53%8.00Maintain11/11/2026
Citizens
Buy17.00+320.79%-Maintain11/11/2026
Citizens
Buy17.00+320.79%-Maintain19/10/2026
Citizens
Buy17.00+320.79%-Maintain16/10/2026

Earnings

Latest Release
10/11/2026
EPS / Forecast
-0.46 / -0.14
Revenue / Forecast
1.13M / 1.54M
EPS Revisions
Last 90 days

Compare IRD to Peers and Sector

Metrics to compare
IRD
Peers
Sector
Relationship
P/E Ratio
−2.9x−1.5x−0.2x
PEG Ratio
0.31−0.060.00
Price/Book
10.2x1.9x2.6x
Price / LTM Sales
49.3x101.1x2.7x
Upside (Analyst Target)
245.1%641.2%66.0%
Fair Value Upside
Unlock7.3%10.8%Unlock

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. Opus Genetics, Inc. was formerly known as Ocuphire Pharma, Inc. and changed its name to Opus Genetics, Inc. in November 2020. The company was founded in 2018 and is headquartered in Durham, North Carolina.

Employees
28

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
9.36M9.68%37.26M
Other Institutional Investors
59.74M61.81%237.76M
Public Companies & Retail Investors
27.55M28.51%109.66M
Total
96.65M100.00%384.68M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Caligan Partners, LP6.29%6,077,08424,187
BlackRock, Inc.5.22%5,044,84720,078

People Also Watch

2.570
ALEC
+1.18%
36.48
PCRX
+0.05%
28.95
PRDO
-0.14%
22.73
OSPN
+1.88%
32.320
SRZN
+2.25%

FAQ

What Is the Opus Genetics (NASDAQ: IRD) Share Price Today?

The Opus Genetics stock price today is 4.040 USD.

What Stock Exchange Does Opus Genetics (IRD) Trade On?

Opus Genetics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Opus Genetics?

The stock symbol (also called a 'ticker') for Opus Genetics is "IRD."

What Is the Current Opus Genetics Market Capitalisation?

As of today, Opus Genetics (NASDAQ: IRD) market cap is 390.480M USD.

What Is Opus Genetics's (IRD) Earnings Per Share (TTM)?

The Opus Genetics EPS is currently -1.50 (Trailing Twelve Months).

When Is the Next Opus Genetics Earnings Date?

Opus Genetics's next earnings report will be released on 11/03/2027.

Is IRD a Buy or Sell From a Technical Analyst Perspective?

Based on today's Opus Genetics moving averages and other technical indicators, the daily buy/sell signal for IRD stock is Neutral.

How Many Times Has Opus Genetics Stock Split?

Opus Genetics has split 3 times. (See the IRD stock split history page for full effective split date and price information.)

How Many Employees Does Opus Genetics Have?

Opus Genetics has 28 employees, based on their latest Companies House report.

What is the current trading status of Opus Genetics (NASDAQ: IRD)?

As of 17/11/2026, Opus Genetics (IRD) is trading at a share price of 4.040 USD, with a previous close of 4.040 USD. The stock has fluctuated within a day range of 3.885 USD to 4.080 USD, while its 52-week range spans from 1.700 USD to 7.070 USD.

What Is Opus Genetics (IRD) Price Target According to Analysts?

The average 12-month price target for Opus Genetics is 13.941 USD, with a high estimate of 20 USD and a low estimate of 8 USD. 17 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +245.08% Upside potential.

What Is the IRD Premarket Price?

IRD's last pre-market stock price is 3.950 USD. The pre-market share volume is 2,880.000, and the stock has decreased by -0.030, or -0.750%.

What Is the IRD After Hours Price?

IRD's last after hours stock price is 4.100 USD, the stock has decreased by 0.060, or 1.490%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.